Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for ...

Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish ...

AI agents will play a vital role in software programming and cybersecurity, but they will also change enterprise workflows ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, ...

The National Systems Contractors Association (NSCA), together with Ignite, brought the inaugural Excellence in Business ...

That’s why the Sturgeon Bay theater company is giving the public a glimpse behind the curtain with a new TAP Talks series.

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO ...

A state panel has made its recommendations for how the first round of funding from a major $638 million settlement with ...

Regulatory Updates Key Business Developments * In December 2017, Legend Biotech entered into an exclusive worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...